Bifidobacterium breve with α-Linolenic Acid and Linoleic Acid Alters Fatty Acid Metabolism in the Maternal Separation Model of Irritable Bowel Syndrome

Barrett, Eva; Fitzgerald, Patrick; Dinan, Timothy G.; Cryan, John F.; Ross, R. Paul; Quigley, Eamonn Martin; Shanahan, Fergus; Kiely, Barry; Fitzgerald, Gerald F.; O’Toole, Paul W.; Stanton, Catherine

doi:10.1371/journal.pone.0048159

Cited by 31 publications

(22 citation statements)

References 69 publications

(88 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These actions are characteristic of specialized pro-resolving mediators37 and define these novel n-3 DPA products as immunoresolvents. In view of the role of lipid mediators in inflammation and its timely resolution1437, the n-3 DPA metabolome documented herein may mediate some of the beneficial actions associated with probiotic dietary supplementation40. Moreover, these new n-3 immunoresolvents may also serve as a compensatory mechanism in people with elevated n-3 DPA levels and lower circulating DHA levels21 to compensate for losses in DHA SPM-regulated leukocyte-mediated tissue damage and timely resolution of acute inflammation.…”

Section: Discussionmentioning

confidence: 92%

Novel n-3 Immunoresolvents: Structures and Actions

Dalli

Colas

Serhan

2013

Sci Rep

211

273

View full text Add to dashboard Cite

Resolution of inflammation is now held to be an active process where autacoids promote homeostasis. Using functional-metabololipidomics and in vivo systems, herein we report that endogenous n-3 docosapentaenoic (DPA) acid is converted during inflammation-resolution in mice and by human leukocytes to novel n-3 products congenerous to D-series resolvins (Rv), protectins (PD) and maresins (MaR), termed specialized pro-resolving mediators (SPM). The new n-3 DPA structures include 7,8,17-trihydroxy-9,11,13,15E,19Z-docosapentaenoic acid (RvD1n-3 DPA), 7,14-dihydroxy-8,10,12,16Z,19Z-docosapentaenoic acid (MaR1n-3 DPA) and related bioactive products. Each n-3 DPA-SPM displayed protective actions from second organ injury and reduced systemic inflammation in ischemia-reperfusion. The n-3 DPA-SPM, including RvD1n-3 DPA and MaR1n-3 DPA, each exerted potent leukocyte directed actions in vivo. With human leukocytes each n-3 DPA-SPM reduced neutrophil chemotaxis, adhesion and enhanced macrophage phagocytosis. Together, these findings demonstrate that n-3 DPA is converted to novel immunoresolvents with actions comparable to resolvins and are likely produced in humans when n-3 DPA is elevated.

show abstract

Section: Discussionmentioning

confidence: 92%

Novel n-3 Immunoresolvents: Structures and Actions

Dalli

Colas

Serhan

2013

Sci Rep

211

273

View full text Add to dashboard Cite

show abstract

“…However, in specific dietary supplementation, ALA increased tissue concentrations of EPA and DHA174142, in fact, we have previously demonstrated that supplementing an ALA enriched diet with B. breve NCIMB 702258 and B. breve DPC 6330 increased tissue concentrations of EPA, docosapentaenoic acid and DHA, compared with dietary ALA alone1719, favouring DHA biosynthesis. Flaxseed has thus emerged as an important functional food ingredient, as it is one of the richest sources of ALA (1 tablespoon of flaxseed oil contains ~8 g ALA)43.…”

mentioning

confidence: 87%

Bifidobacterium breve with α-linolenic acid alters the composition, distribution and transcription factor activity associated with metabolism and absorption of fat

Patterson¹,

Wall²,

Lisai³

et al. 2017

Sci Rep

Self Cite

View full text Add to dashboard Cite

This study focused on the mechanisms that fatty acid conjugating strains - Bifidobacterium breve NCIMB 702258 and Bifidobacterium breve DPC 6330 - influence lipid metabolism when ingested with α-linolenic acid (ALA) enriched diet. Four groups of BALB/c mice received ALA enriched diet (3% (w/w)) either alone or in combination with B. breve NCIMB 702258 or B. breve DPC 6330 (109 CFU/day) or unsupplemented control diet for six weeks. The overall n-3 PUFA score was increased in all groups receiving the ALA enriched diet. Hepatic peroxisomal beta oxidation increased following supplementation of the ALA enriched diet with B. breve (P < 0.05) and so the ability of the strains to produce c9t11 conjugated linoleic acid (CLA) was identified in adipose tissue. Furthermore, a strain specific effect of B. breve NCIMB 702258 was found on the endocannabinoid system (ECS). Liver triglycerides (TAG) were reduced following ALA supplementation, compared with unsupplemented controls (P < 0.01) while intervention with B. breve further reduced liver TAG (P < 0.01), compared with the ALA enriched control. These data indicate that the interactions of the gut microbiota with fatty acid metabolism directly affect host health by modulating n-3 PUFA score and the ECS.

show abstract

“…However, in maternally separated rats, dietary supplementation with fish oil reduces neither the response to colon distension nor the level of pro-inflammatory cytokines in colonic tissue (van Diest et al, 2015). Another study combined the supplementation with CLA and probiotics ( B.breve DPC6330) (Barrett et al, 2012). Groups of 15 rats were either separated from their mothers or not, and fed with probiotic, probiotic together with LA and ALA, or placebo.…”

Section: Pufas In Irritable Bowel Syndromementioning

confidence: 99%

“…Groups of 15 rats were either separated from their mothers or not, and fed with probiotic, probiotic together with LA and ALA, or placebo. The supplementation provided significant changes in lipid composition in the rats' serum, colonic tissue and prefrontal cortex, but failed to clearly change the colonic hypersensitivity measured by colon distension (Barrett et al, 2012). Of note, the use of human intestine bacteria ( B. breve, strain DPC6330) affected the FA metabolism in maternally separated rats to a greater extent than in non-separated animals.…”

Section: Pufas In Irritable Bowel Syndromementioning

confidence: 99%

Polyunsaturated Fatty Acids and Their Derivatives: Therapeutic Value for Inflammatory, Functional Gastrointestinal Disorders, and Colorectal Cancer

2016

View full text Add to dashboard Cite

Polyunsaturated fatty acids (PUFAs) are bioactive lipids which modulate inflammation and immunity. They gained recognition in nutritional therapy and are recommended dietary supplements. There is a growing body of evidence suggesting the usefulness of PUFAs in active therapy of various gastrointestinal (GI) diseases. In this review we briefly cover the systematics of PUFAs and their metabolites, and elaborate on their possible use in inflammatory bowel disease (IBD), functional gastrointestinal disorders (FGIDs) with focus on irritable bowel syndrome (IBS), and colorectal cancer (CRC). Each section describes the latest findings from in vitro and in vivo studies, with reports of clinical interventions when available.

show abstract

Bifidobacterium breve with α-Linolenic Acid and Linoleic Acid Alters Fatty Acid Metabolism in the Maternal Separation Model of Irritable Bowel Syndrome

Cited by 31 publications

References 69 publications

Novel n-3 Immunoresolvents: Structures and Actions

Novel n-3 Immunoresolvents: Structures and Actions

Bifidobacterium breve with α-linolenic acid alters the composition, distribution and transcription factor activity associated with metabolism and absorption of fat

Polyunsaturated Fatty Acids and Their Derivatives: Therapeutic Value for Inflammatory, Functional Gastrointestinal Disorders, and Colorectal Cancer

Contact Info

Product

Resources

About